Long-term use of statins reduces the risk of hospitalization for dementia.

[1]  B. Strom.  Overview of Automated Databases in Pharmacoepidemiology , 2013 .

[2]  G. Mancia,et al.  External adjustment for unmeasured confounders improved drug-outcome association estimates based on health care utilization data. , 2012, Journal of clinical epidemiology.

[3]  Christos G Mihos,et al.  Mechanisms and Clinical Evidence of the Pleiotropic Effects of the Hydroxy-Methyl-Glutaryl-CoA Reductase Inhibitors in Central Nervous System Disorders: A Comprehensive Review , 2012, The International journal of neuroscience.

[4]  A. Zwinderman,et al.  Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. , 2012, JAMA.

[5]  C. Otte,et al.  Statin use and risk of depression in patients with coronary heart disease: longitudinal data from the Heart and Soul Study. , 2012, The Journal of clinical psychiatry.

[6]  Zheng-rong Wang,et al.  The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta‐analysis of longitudinal studies , 2011, International journal of clinical practice.

[7]  D. Selkoe,et al.  Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. , 2011, Archives of neurology.

[8]  K. Nakashima,et al.  [The Rotterdam study]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[9]  D. Selkoe,et al.  Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. , 2011, Archives of neurology.

[10]  Michael L. Johnson,et al.  Risk factors for dementia in patients over 65 with diabetes , 2011, International journal of geriatric psychiatry.

[11]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[12]  Amy L. Byers,et al.  Depression and risk of developing dementia , 2011, Nature Reviews Neurology.

[13]  Til Stürmer,et al.  Nonexperimental comparative effectiveness research using linked healthcare databases. , 2011, Epidemiology.

[14]  Chih-Cheng Hsu,et al.  Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. , 2011, Journal of Alzheimer's disease : JAD.

[15]  L. Ferrucci,et al.  Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment , 2010, Journal of Epidemiology & Community Health.

[16]  M. Elkind,et al.  3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. , 2010, Archives of neurology.

[17]  M. Kivipelto,et al.  Midlife Serum Cholesterol and Increased Risk of Alzheimer’s and Vascular Dementia Three Decades Later , 2009, Dementia and Geriatric Cognitive Disorders.

[18]  J Shepherd,et al.  The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials , 2009, BMJ : British Medical Journal.

[19]  G. Ransmayr.  Cholesterin und Statine beim Morbus Alzheimer , 2003, Wiener Medizinische Wochenschrift.

[20]  Spyridon S Marinopoulos,et al.  The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. , 2008, Journal of clinical epidemiology.

[21]  A Hofman,et al.  Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[22]  S. Suissa.  Immeasurable time bias in observational studies of drug effects on mortality. , 2008, American journal of epidemiology.

[23]  J D Kalbfleisch,et al.  Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study , 2008, Neurology.

[24]  D. A. Bennett,et al.  Statins, incident Alzheimer disease, change in cognitive function, and neuropathology , 2008, Neurology.

[25]  G. Cesana,et al.  Pharmacoepidemiological research and the linking of electronic healthcare databases available in the Italian region of Lombardy , 2008 .

[26]  R. Huupponen,et al.  Long-term persistence with statin therapy: a nationwide register study in Finland. , 2008, Clinical therapeutics.

[27]  Lewis E Kazis,et al.  Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease , 2007, BMC medicine.

[28]  Alexandria,et al.  Recommendations for Evaluating Compliance and Persistence With Hypertension Therapy Using Retrospective Data , 2006, Hypertension.

[29]  S. Schneeweiss.  Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics , 2006, Pharmacoepidemiology and drug safety.

[30]  Constantine Lyketsos,et al.  Dementia and Alzheimer's Disease Incidence in Relationship to Cardiovascular Disease in the Cardiovascular Health Study Cohort , 2005, Journal of the American Geriatrics Society.

[31]  J. Avorn,et al.  A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.

[32]  U. Gresser,et al.  Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies. , 2004, European journal of medical research.

[33]  G. McGwin,et al.  Association between Statin Use and Alzheimer’s Disease , 2004, Neuroepidemiology.

[34]  W. Ray,et al.  Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.

[35]  S Rabe-Hesketh,et al.  Head injury as a risk factor for Alzheimer’s disease: the evidence 10 years on; a partial replication , 2003, Journal of neurology, neurosurgery, and psychiatry.

[36]  M. Etminan,et al.  The Role of Lipid‐Lowering Drugs in Cognitive Function: A Meta‐Analysis of Observational Studies , 2003, Pharmacotherapy.

[37]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[38]  Michael E. Ezell,et al.  The accuracy of medicare claims data in identifying Alzheimer's disease. , 2002, Journal of clinical epidemiology.

[39]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[40]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[41]  S Greenland,et al.  Sensitivity Analysis, Monte Carlo Risk Analysis, and Bayesian Uncertainty Assessment , 2001, Risk analysis : an official publication of the Society for Risk Analysis.

[42]  G. Román.  Diagnosis of vascular dementia and Alzheimer's disease. , 2001, International journal of clinical practice. Supplement.

[43]  M. Dimatteo,et al.  Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. , 2000, Archives of internal medicine.

[44]  P. Macfarlane,et al.  The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. , 1999, The American journal of cardiology.

[45]  K. Henry,et al.  "Mixed dementia": adequate or antiquated? A critical review. , 1997, The American journal of geriatric psychiatry.

[46]  J. J. Claus,et al.  Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam study , 1994, BMJ.

[47]  G. Lenzi,et al.  Serum lipoprotein pattern variations in dementia and ischemic stroke , 1990, Acta neurologica Scandinavica.

[48]  Jennifer L. Kelsey,et al.  Methods in Observational Epidemiology , 1986 .

[49]  N. Breslow,et al.  The analysis of case-control studies , 1980 .